Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diclofenac in rheumatoid disease.

B L Treadwell, J M Tweed

    The New Zealand Medical Journal
    |January 24, 1979
    PubMed
    Summary

    Diclofenac, a new phenyl acetic-acid derivative, showed similar benefits to aspirin for rheumatoid disease. Diclofenac improved morning stiffness and reduced dyspepsia, while aspirin more effectively lowered the sedimentation rate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The management of rheumatoid arthritis.

    The New Zealand medical journal·1994
    Same author

    Psoriatic arthritis: clinical subgroups and histocompatibility antigens.

    Annals of the rheumatic diseases·1987
    Same author

    Sea urchin spine synovitis.

    The New Zealand medical journal·1984
    Same author

    Nabumetone, a new non-steroidal anti-inflammatory drug: a comparison with naproxen.

    The New Zealand medical journal·1983
    Same author

    Piroxicam in the management of rheumatoid arthritis: a comparison with naproxen.

    The New Zealand medical journal·1982
    Same author

    Fibromyalgia or the fibrositis syndrome: a new look.

    The New Zealand medical journal·1981

    Area of Science:

    • Rheumatology
    • Pharmacology

    Background:

    • Rheumatoid disease management often involves nonsteroidal anti-inflammatory drugs (NSAIDs).
    • A new phenyl acetic-acid derivative, diclofenac, was developed for its anti-inflammatory properties.

    Purpose of the Study:

    • To assess the clinical activity and side effects of diclofenac.
    • To compare diclofenac with aspirin in patients with rheumatoid disease.

    Main Methods:

    • A double-blind, crossover study involving 24 patients with rheumatoid disease.
    • Patients received diclofenac 25 mg four times daily (q.i.d.) or aspirin 750 mg q.i.d. for four weeks each.

    Main Results:

    • Both drugs demonstrated similar overall benefits.
    • Diclofenac showed improvements in morning stiffness and a lower incidence of dyspepsia compared to aspirin.
    • Aspirin led to a more significant reduction in the sedimentation rate.
    • One patient on diclofenac experienced elevated liver enzymes; another had elevated lactate dehydrogenase.

    Conclusions:

    • Diclofenac is an effective analgesic and anti-inflammatory agent for rheumatoid disease.
    • Diclofenac presents a favorable side effect profile regarding gastrointestinal issues compared to aspirin.
    • Further monitoring for liver enzymes and lactate dehydrogenase is warranted.

    Related Experiment Videos